The ten biggest drugmakers in the world want faster, more efficient R&D and claim a new non-profit organisation they formed last week is the solution to the industries development bottlenecks.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Almac, BioStorage Technologies and ACM Global.
The European Medicines Agency (EMA) has recommended a recall of Acino’s generic Plavix (clopidogrel bisulfate) because of alleged failings in GMP at the API production facility.
Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I projects.
Albany Molecular Research Inc (AMRI) faced a “challenging headwind” as 2008 drew to a close but still managed to boost its revenues by 19 per cent to $56.4m in the fourth quarter of 2008.
New Sanofi Aventis chief Christopher Viebacher has virtually ruled out major acquisitions, eschewing the trend started by Pfizer’s $68bn (€53bn) swoop for Wyeth in favour of an anti-mega merger stance like that adopted by UK rival GSK.
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
GlaxoSmithKline’s head of North American operations, Chris Viehbacher, is to takeover as chief operating officer (CEO) at Sanofi-Aventis after he missed out on the top spot at GSK last year.
Switzerland-based Schweizerhall appears to have circumnavigated
patent law, with approval of its generic version of Bristol-Myers
Squibb's (BSM) and Sanofi-Aventis' Plavix (clopidogrel bisulfate)
in Germany "expected...
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim
the fat and save cash, months after first revealing that big
changes would be on the cards.
French pharmaceutical company, Sanofi-Aventis, reported an increase
in sales for the fourth quarter with its vaccine business
continuing to impress. The company's performance precedes two
upcoming decisions later this year that...
The growth in the global pharmaceutical continued to slow in 2004,
with a 7 per cent hike to $550 billion, as the sector felt the
effects of increased pricing pressure and the expanding market for
lower-cost generic drugs, reports...
